# WGS GeneDx Holdings Corp.

1. [Home](https://finlab.finance/en)
2. [U.S. Stocks](https://finlab.finance/en/stocks/us)
3. GeneDx Holdings Corp.(WGS)

Healthcare

49.24 USD Close 11/19

Since 2024-12-20 -36.4%

Close 11/19

* Open

  52.74

* High

  54.80

* Low

  49.09

* Prev close

  51.96

* Volume

  917.42K

* Amplitude

  10.99%

* P/B

  6.0

* Revenue YoY (TTM)

  +14.6%

52W 32.21 170.87

FinLab Studio

From GeneDx Holdings Corp. to every stock like it

AI finds several complementary traits of GeneDx Holdings Corp. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

[Screen stocks like GeneDx Holdings Corp.](https://studio.finlab.finance/en/stocks/us/WGS)

## Is GeneDx Holdings Corp. a buy? Fundamentals and valuation first

As of 2026-11-19

Valuation: Pricey, Quality: Weak, Growth: Weak, Momentum: Weak.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.

TTM P/E -13.1 N/A

Price / book 6.0 87th percentile · Expensive

Free-cash-flow yield (%) -6.9 31th percentile · Average

[US Stock Backtest in Python: Price-to-Book Ratio Strategy](https://finlab.finance/en/blog/us-stock-backtest-price-to-book-strategy)[Quality Factor Investing: A US Quality Value Backtest](https://finlab.finance/en/blog/us-quality-value-strategy)

Quality Weak Operating margin, TTM is Average; ROE, TTM is Lagging.

ROE, TTM (%) -45.4 18th percentile · Lagging

Operating margin, TTM (%) -14.7 25th percentile · Average

FCF margin, TTM (%) -22.0 24th percentile · Average

[Quality Factor Investing: A US Quality Value Backtest](https://finlab.finance/en/blog/us-quality-value-strategy)

Growth Weak Revenue growth, TTM YoY is Good, but Diluted EPS growth, TTM YoY is Lagging.

Revenue growth, TTM YoY (%) 14.6 68th percentile · Good

Diluted EPS growth, TTM YoY (%) -6,366.7 1th percentile · Lagging

Momentum Weak All 2 indicators are Lagging.

60-day return (%) -45.5 15th percentile · Lagging

240-day return (%) -69.0 13th percentile · Lagging

[Momentum Trading Strategy: A 12-1 Momentum Backtest](https://finlab.finance/en/blog/us-momentum-strategy)

Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Average.

20-day dollar volume 72,641,726.0 84th percentile · Top

60-day annualized volatility (%) 89.0 76th percentile · Average

[Factor Investing Explained: 10 Classic Factors in US Stocks](https://finlab.finance/en/blog/us-factor-investing)

## GeneDx Holdings Corp. (WGS) today

1 quant signals active · As of 2026-11-19

* Signal [EPS surprise beat 11 events · 60-day win rate 45.5% · +14.19 pp vs market](https://finlab.finance/en/stocks/us/WGS#eps_beat "Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.")

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

[Overview](https://finlab.finance/en/stocks/us/WGS#zone-position)[Peers](https://finlab.finance/en/stocks/us/WGS#zone-peers)[Signal backtests](https://finlab.finance/en/stocks/us/WGS#zone-evidence)

## GeneDx Holdings Corp. (WGS) peers and tracking

Watchlist

This page refreshes daily after the close. Add GeneDx Holdings Corp. to your watchlist to track signal changes on your next visit.

## GeneDx Holdings Corp. (WGS) quant signal backtests

### Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S\&P 500.

### EPS surprise beat

Active · now 284.3%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

[PEAD: Post-Earnings Announcement Drift Backtest](https://finlab.finance/en/blog/us-earnings-surprise-strategy)

12 historical occurrences (since 2022-03-14)

Average forward return after EPS surprise beat

20-day: Win 54.5%, Sample 11, Median +4.7%, Excess +9.1%, Beat mkt rate 45.5%

60-day: Win 45.5%, Sample 11, Median -5.7%, Excess +14.2%, Beat mkt rate 45.5%

120-day: Win 60.0%, Sample 10, Median +19.4%, Excess +85.9%, Beat mkt rate 60.0%

120 days after: historical avg +94.4%

20-day +10.9%

60-day +19.5%

120-day +94.4%

20-day

60-day

120-day

Win

54.5%

45.5%

60.0%

Sample

11

11

10

Median

+4.7%

-5.7%

+19.4%

Excess

+9.1%

+14.2%

+85.9%

Beat mkt rate

45.5%

45.5%

60.0%

Over 10 occurrences, 120-day forward avg gained 94.4%, beat the market by 85.9 pts; win rate 60.0%.

More history: Market-wide momentum baseline, Signals not active now

### Market-wide momentum baseline

> Across 101,368 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.28%, a 58.5% positive-return rate, and +2.97 percentage points of average excess return versus the S\&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S\&P 500 (^GSPC).

### Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

### 52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

8 times historically; 60-day forward avg +19.4%, win rate 50.0%, beating the market by +16.1 pts on average.

### Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

[Momentum Trading Strategy: A 12-1 Momentum Backtest](https://finlab.finance/en/blog/us-momentum-strategy)

8 times historically; 60-day forward avg +39.3%, win rate 66.7%, beating the market by +35.5 pts on average.

### Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

5 times historically; 60-day forward avg -28.9%, win rate 0.0%, beating the market by -30.5 pts on average.

## Method and limits

* Returns use us\_price:adj\_close, adjusted for splits and dividends where available.
* Excess returns use world\_index:^GSPC as the S\&P 500 benchmark proxy.
* Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
* The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
* Snapshot-only tables such as analyst consensus, DCF, us\_ratios, and us\_key\_metrics are intentionally excluded from historical evidence.
* Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.

Further reading

Browse more quantitative analysis in [U.S. Stocks](https://finlab.finance/en/stocks/us). To turn these signals into backtestable rules, read the [Quantitative Trading Guide](https://finlab.finance/en/tools/quant-trading). Definitions of the Sharpe ratio, drawdown and other quant terms are in the [Quant Glossary](https://finlab.finance/en/glossary). Calculate this stock's risk-adjusted return with the [Sharpe Ratio Calculator](https://finlab.finance/en/tools/sharpe-ratio), and to automate the signals read the [Program Trading Guide](https://finlab.finance/en/tools/program-trading).

[Stock](https://finlab.finance/en/stocks/us/WGS)

Source: https://finlab.finance/en/stocks/us/WGS | Data dates: ../2026-11-19
